Cargando…

Chronic Kidney Disease Stage G4 in a Diabetic Patient Improved by Multi-Disciplinary Treatments Based Upon Literature Search for Therapeutic Evidence

In the EMPA-REG OUTCOME trial, sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, reduced incident or worsening nephropathy. In the LEADER trial, a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, resulted in lower rates of the development and progression of diabetic kidn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yanai, Hidekatsu, Yamaguchi, Naoki, Adachi, Hiroki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635773/ https://www.ncbi.nlm.nih.gov/pubmed/36405227 http://dx.doi.org/10.14740/cr1424

Ejemplares similares

The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4
por: Koguchi, Ayako, et al.
Publicado: (2017)

Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

The Low-Dose (7.5 mg/day) Pioglitazone Therapy
por: Yanai, Hidekatsu, et al.
Publicado: (2017)

Clinical, Hematological, Biochemical and Radiological Characteristics for Patients With Splenic Infarction: Case Series With Literature Review
por: Hakoshima, Mariko, et al.
Publicado: (2023)

Diabetic Ketosis Caused by the Insulin Analog Aspart–Induced Anti-Insulin Antibody: Successful Treatment With the Newest Insulin Analog Glulisine
por: Yanai, Hidekatsu, et al.
Publicado: (2011)

The Underlying Mechanisms for Olanzapine-induced Hypertriglyceridemia
por: Adachi, Hiroki, et al.
Publicado: (2012)

Which Factor Determines the Duration Required for Relief of Glucotoxicity by the Intensive Insulin Therapy?
por: Yanai, Hidekatsu, et al.
Publicado: (2018)

What Properties of Sodium-Glucose Cotransporter 2 Inhibitors Determine the Improvement in Hemoglobin A1c and Body Weight?
por: Yanai, Hidekatsu, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy
por: Hakoshima, Mariko, et al.
Publicado: (2018)

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Research ethics in inter- and multi-disciplinary teams: Differences in disciplinary interpretations
por: Mathur, Ambika, et al.
Publicado: (2019)

Therapeutic Drug Monitoring in Epilepsy Clinic: A Multi-Disciplinary Approach
por: Lertsinudom, Sunee, et al.
Publicado: (2014)

Effects of 6-Month Sitagliptin Treatment on Metabolic Parameters in Diabetic Patients Taking Oral Glucocorticoids: A Retrospective Cohort Study
por: Katsuyama, Hisayuki, et al.
Publicado: (2015)

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

ISVH – A multi-disciplinary society
Publicado: (2006)

203 Optimization of Posaconazole (PCZ) Dosing with Multi-disciplinary Therapeutic Monitoring (TDM) Protocol
por: Pettit, Natasha, et al.
Publicado: (2014)

Role of ICT for multi-disciplinary applications in 2030
por: Ligthart, Leo P, et al.
Publicado: (2016)

Mental handicap: a multi-disciplinary approach
Publicado: (1986)

Myelo-meningocele: A multi-disciplinary problem
por: Nnamdi, Ibe Michael Onwuzuruike
Publicado: (2014)

Bone Oncology—An emerging multi-disciplinary specialty
por: Coleman, Robert, et al.
Publicado: (2012)

A multi-disciplinary view on earthquake science
Publicado: (2022)

Multi-Disciplinary Approach to Skull Base Paragangliomas
por: Curry, Steven D., et al.
Publicado: (2023)

Investigating the efficiency of lung multi‐disciplinary team meetings—A mixed methods study of eight lung multi‐disciplinary teams
por: Zasada, Magdalena, et al.
Publicado: (2023)

Effects of Intake of Fish or Fish Oils on the Development of Diabetes
por: Yanai, Hidekatsu, et al.
Publicado: (2015)

Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

The need for a multi-disciplinary reflection about frailty and cognitive impairment in chronic kidney disease
por: Farisco, Michele, et al.
Publicado: (2022)

Delivering cancer services: a multi-disciplinary approach
por: Tho, LM, et al.
Publicado: (2006)

Multi-disciplinary planning in health care: a review
por: Leeftink, A. G., et al.
Publicado: (2018)

Developing Industrial CPS: A Multi-Disciplinary Challenge
por: Hoffmann, Martin W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_44k6mfr255auui9mioih7pqg1k